il13ralpha2-specific, hinge-optimized, 41bb-costimulatory car/truncated cd19-expressing autologous t lymphocytes
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 18, 2015 (NCT02208362)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- il13ralpha2-specific, hinge-optimized, 41bb-costimulatory car/truncated cd19-expressing autologous t lymphocytes
- il13rα2-specific, hinge-optimized, 41bb-costimulatory car/truncated cd19-expressing autologous t lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02208362 | Phase 1 | May 18, 2015 | City of Hope National Medical Center, National Cancer Institute (NCI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2015 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2015 |
2 organizations
Page 1 / 1